Toll-like receptor 1 (TLR1) (TLR1)

Toll-like receptor 1 (TLR1) is a type I transmembrane protein and a member of the pattern recognition receptor (PRR) family, essential for the innate immune system's ability to detect pathogens. It functions primarily as a heterodimer with Toll-like receptor 2 (TLR2) to specifically recognize triacylated lipopeptides, which are components of the cell walls of various bacteria and mycobacteria. Upon ligand recognition, the TLR1/2 complex recruits the adaptor protein MyD88, triggering a downstream signaling cascade that activates the NF-kappaB and MAPK pathways. This activation leads to the production of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, which are vital for initiating an effective immune response and shaping adaptive immunity. TLR1 is involved in the pathogenesis of several conditions, including infectious diseases like leprosy and tuberculosis, as well as inflammatory disorders and cancer. Consequently, TLR1/2 agonists are being developed as potent vaccine adjuvants and anti-tumor agents, while antagonists are explored for their potential to mitigate excessive inflammation and autoimmune responses.

Other names

CD281TILToll-like receptor 1Toll/interleukin-1 receptor-like protein

Agonists bind to the TLR1/2 heterodimer, inducing a conformational change that facilitates the recruitment of the adaptor protein MyD88. This initiates a signaling cascade involving IRAK kinases and TRAF6, leading to the activation of the NF-kappaB and MAPK pathways, which results in the transcription of pro-inflammatory cytokines and chemokines. Antagonists work by preventing ligand binding or inhibiting the dimerization of TLR1 and TLR2.